Is hydroxyapatite toothpaste safe?

Hydroxyapatite (HA) is the calcium-phosphate mineral that makes up most of tooth enamel. In toothpaste, synthetic HA is used as a biomimetic ingredient—chemically similar to tooth mineral, not identical to the carbonated “bioapatite” in living enamel. Safety questions usually focus less on the mineral name and more on particle form (especially nano), concentration, how the product is used, and who is using it.

This page explains what regulators and scientific committees have actually said. It is educational, not medical advice. If you have active decay, pain, gum disease, or you are changing a child’s fluoride routine, talk with a dentist.

The short answer

For ordinary toothpaste use, hydroxyapatite has a long market history (Japan since 1980) and a detailed European scientific review for specified nano forms. “Safe” in that regulatory sense means: this characterised material, at these concentrations, in toothpaste or mouthwash, under reasonably foreseeable oral-care use—not “every nano-HA product, every claim, every age group, forever.”

Microcrystalline (larger-particle) HA used in several clinical caries trials is not the same regulatory object as EU-defined nano-HA. Nano safety opinions are morphology-specific. For particle-size context, see nano-hydroxyapatite vs hydroxyapatite.

What “nano” means here

In EU cosmetics law, a nanomaterial has at least one dimension in the nanometre range (conventionally discussed as about 1–100 nm). Oral-care literature often describes commercial nano-HA roughly in the 20–100 nm range, commonly as rods.

That size is why regulators looked carefully at:

• Whether particles could be taken up by mouth tissues
• What happens if paste is swallowed
• Whether shape (rod vs needle) changes the risk picture
• Whether coatings or surface modifications change behaviour

Smaller is not automatically more dangerous—and “nano on the label” is not automatically the same material the EU committee assessed.

An example characterisation from the 2023 SCCS dossier materials (nanoXIM CarePaste) reported median length around 28 nm and median width around 15 nm for a rod-shaped grade. Submission IV’s assessed materials included particles with a maximum length cited at 122 ± 43 nm. Those numbers illustrate the scale regulators had in mind; they are not a substitute for a brand’s own certificate of analysis.

Aspect ratio, in plain language

Aspect ratio here means length divided by width. A short, stubby rod has a low aspect ratio. A long, thin particle has a high one. Needles are an extreme shape category that SCCS explicitly excluded from its “safe” conclusions. That is why vague marketing (“nano minerals!”) is not the same as regulatory clearance for a characterised rod grade.

Micro-HA vs nano-HA on a safety page

Several modern caries non-inferiority trials (Schlagenhauf 2019; Paszynska 2021 and 2023) used about 10% microcrystalline HA, not necessarily nano. Micro particles are larger (secondary reviews sometimes describe roughly a few micrometres). They are not automatically “unsafe”; they are simply outside the EU nanomaterial Annex III framing that drives most “is nano safe?” searches.

Writers and shoppers should not cite a micro-HA clinical trial as proof that an uncharacterised nano grade is SCCS-aligned—or vice versa.

EU scientific opinions (SCCS)

The European Commission’s Scientific Committee on Consumer Safety (SCCS) has issued key opinions on hydroxyapatite (nano) in oral cosmetics.

2023 opinion (SCCS/1648/22)

The March 2023 final opinion concluded that hydroxyapatite (nano) is safe at:

• up to 10% in toothpaste
• up to 0.465% in mouthwash

Only for material that is:

• rod-shaped
• at least 95.8% of particles (by number) with aspect ratio < 3
• the remaining ≤ 4.2% with aspect ratio ≤ 4.9
• not coated or surface-modified

The opinion does not apply to needle-shaped particles. It also does not cover sprayable products that could expose lungs by inhalation (no adequate lung-exposure data).

Regulation (EU) 2024/858 — the legal limit in force

Commission Regulation (EU) 2024/858 translated the 2023 SCCS conclusion into Cosmetics Regulation Annex III restrictions for hydroxyapatite (nano): maximum 10% toothpaste / 0.465% mouthwash, with the morphology limits above, and no inhalation-exposure uses. Non-compliant products faced placement and making-available bans phased in during 2025.

That regulation is the legal cosmetics ceiling to cite when readers ask “what is currently allowed in the EU?”—unless and until Annex III is formally amended.

2025 opinion — Submission IV (SCCS/1677/25)

In June 2025 the SCCS adopted Submission IV. Based on new industry data, it concluded that hydroxyapatite (nano) is safe up to:

• 29.5% in toothpaste
• 10% in mouthwash

Only for material that is:

• rod-shaped
• at least 87% of particles with aspect ratio ≤ 3, remaining ≤ 13% with aspect ratio ≤ 9
• uncoated / not surface-modified
• with maximum particle length in the assessed material of 122 ± 43 nm
• still not for needle-shaped particles

The committee’s rationale emphasises: no mutagenic hazard / cytotoxicity / inflammatory signal at high concentrations in buccal mucosa models; mucosal uptake considered negligible; ingested particles expected to dissolve in gastric fluid, so no nano-specific systemic concern from that pathway.

Japan: long market history

Japan has sold HA toothpaste since 1980 (Apadent first; Apagard followed in 1985). In 1993, Japanese authorities recognised Sangi’s proprietary HA pathway as an anti-caries agent (“Medical Hydroxyapatite”). That history is cumulative exposure and regulatory acceptance in one major market—not a controlled lifelong epidemiology study of every modern nano grade. Company marketing figures for total tubes sold are not independent epidemiology.

The NASA-linked origin story is often compressed in marketing. NASA patented a crystal-growth repair concept in the early 1970s; Sangi commercialised particulate HA toothpaste. That history supports familiarity and long consumer use in Japan—it does not by itself answer every modern nano morphology question in Europe.

United States: cosmetics vs anticaries drugs

In the US, fluoride is the OTC monograph anticaries active (FDA Monograph M021) within specified concentrations. HA toothpastes are generally sold as cosmetics (cleaning, whitening appearance, comfort-oriented sensitivity language)—not as FDA monograph anticaries drugs. Educational discussion of published trials is different from labelling a paste with drug-style “prevents cavities” claims.

The ADA Seal of Acceptance for cavity-protection claims requires fluoride. HA pastes without fluoride generally will not carry that Seal for anticaries. That is about Seal criteria and evidence pathways, not a statement that HA is “banned” or “unsafe.”

NASA Spinoff reporting has mentioned FDA-pathway activity for some HA anti-sensitivity products (for example in the Sangi lineage). Those pathways are product-specific. Do not generalise “FDA cleared for sensitivity” to every HA toothpaste, and do not invent “FDA-approved for cavity prevention” language—that claim is not supported for HA as a monograph anticaries active.

What US shoppers can usefully ask

• Is this marketed as a cosmetic toothpaste or with drug-style anticaries claims?
• Does the label disclose % HA, and nano vs micro (or both)?
• For cavity risk, what does my dentist recommend—especially for children?

Absence of an ADA anticaries Seal on a fluoride-free HA paste is expected under current Seal rules. It is not, by itself, a toxicity finding.

How clinical use informs the safety conversation

Safety and effectiveness are related but not identical. HA’s better-supported clinical use cases—such as dentin hypersensitivity reduction in pooled trials, and non-inferiority caries endpoints in a small set of industry-funded RCTs—do not prove every safety question. They do show that specific HA toothpastes have been used under trial conditions in children and adults without a pattern of dramatic adverse-event stories dominating those publications.

Cross-cutting limits of the clinical literature still apply: sample sizes in the hundreds, durations often 6–18 months, frequent industry funding, and generous non-inferiority margins. Those limits matter more for “does it prevent cavities as robustly as fluoride’s decades of trials?” than for “is the mineral generally tolerated when brushed?”

Swallowing toothpaste

Toothpaste is for brushing. Spit after brushing.

For hydroxyapatite specifically:

• HA is the mineral of bone and teeth.
• Accidental swallowing of ordinary brushing amounts is generally framed as low systemic risk compared with chronic excess fluoride intake during enamel formation (dental fluorosis risk in young children).
• The 2025 SCCS opinion states that unintentionally ingested HAP nanoparticles are expected to dissolve in gastric fluid and therefore do not raise a nano-specific systemic concern in that assessment.

That is one reason some parents look at fluoride-free HA pastes for toddlers who swallow paste. It is a real trade-off discussion—not a reason to ignore caries risk. For the parenting angle, see hydroxyapatite toothpaste for kids and babies. Fluoride remains the better-evidenced caries preventive overall; high-caries-risk children should follow a dentist’s plan.

Who should be especially careful

• Anyone with unexplained mouth irritation after switching pastes — stop and check ingredients; see a dentist if it persists (more in hydroxyapatite side effects).
• People seeking disease treatment from toothpaste alone — HA toothpaste does not treat periodontitis or replace fillings.
• Buyers assuming every “nano-HA” label matches SCCS specs — morphology, aspect ratio, and coating must match what was assessed. Public characterisation is not always published.

Pregnancy and breastfeeding

We did not find dedicated pregnancy RCTs of HA toothpaste in the shared research base. Given HA’s biocompatibility narrative and oral (not systemic drug) use pattern, many clinicians treat standard toothpaste use as routine hygiene—but ask your obstetric and dental team. Do not use web copy as a pregnancy protocol.

If nausea from strong mint makes brushing difficult in pregnancy, that is a practical comfort issue—not an HA-specific hazard. Flavour strength varies by brand; choose what you can tolerate and keep cleaning twice daily if possible.

Mouthwash, sprays, and other formats

SCCS toothpaste conclusions do not automatically extend to every delivery format:

• Mouthwash maxima in the 2023 opinion / Regulation 2024/858 framework are much lower (0.465% nano-HA) than toothpaste (10%).
• Submission IV assessed higher mouthwash concentrations scientifically (10%) for specified rods—again, scientific opinion versus legal annex status must be kept separate.
• Sprayable products with inhalation risk were excluded from the safe conclusions because lung-exposure data were inadequate.

If a product is not a standard spit-out toothpaste, do not assume the toothpaste opinion covers it.

Reading a label without false reassurance

Useful label habits:

1. Find whether HA is listed, and whether % is disclosed (many clinical caries trials used 10%).
2. Note nano, micro, or blend language—and treat missing morphology data as a gap, not a free pass.
3. Scan the rest of the formula for allergens you already know (flavour oils, detergents).
4. Ignore “NASA invented this toothpaste” simplifications; use verified history instead.

This site is operated in connection with Klyyr, which sells a fluoride-free paste with 10% HA (nano + micro blend). Particle morphology, aspect ratio, and coating for that nano fraction are not published here, so this guide does not claim SCCS aspect-ratio compliance for that product. Confirmed product facts belong on the brand page; safety articles stay with regulator text and primary studies.

How to read this page

We prioritise peer-reviewed trials and regulator opinions. Many HA clinical studies are manufacturer-funded; we say so when it matters for interpretation. Fluoride remains the best-studied anticaries toothpaste active worldwide. “Safe for specified nano-HA under SCCS conditions” is not the same sentence as “every fluoride-free paste is the right choice for every child.”

Bottom line

Hydroxyapatite toothpaste has substantial regulatory and historical support for ordinary oral use when the particle story is taken seriously. EU “safe” conclusions for nano-HA are precise: rod-shaped, uncoated, aspect-ratio-limited material at stated concentrations—not a blank cheque for every nano marketing claim. Current EU law still centres on the 10% / 0.465% framework from Regulation 2024/858 unless Annex III has been amended. In the US, absence of an ADA anticaries Seal for fluoride-free HA pastes reflects Seal/monograph structure, not a poison label.

If something hurts, bleeds, or looks infected, see a dentist—toothpaste choice is secondary.

Explore next

• Hydroxyapatite side effects — what people usually mean by “side effects”
• Nano-hydroxyapatite vs hydroxyapatite — size, shape, and label language
• Hydroxyapatite toothpaste for kids — swallowing, fluorosis, and when fluoride still matters
• What is hydroxyapatite? — the primer